E-Learning Center
Join Our Network
OncoFacts

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Expert Reviews in Hematology: Practical Clinical Application of the 2010 Advances in Hematology


Register Now

Great Debates and Updates in Hematologic Malignancies

April 28-30, 2011

New York, New York

 

ACCME

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 19.0 of AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend/Target Audience
This educational activity is primarily targeted to academic and community hematologists and oncologists, and secondarily to oncology nurses and other health care professionals interested in the management of patients with hematologic malignancies.

Learning Objectives
After successful completion of the proposed activity, participants will

  • Have increased awareness/knowledge regarding:
    • The evolving role of stem cell transplantation in the wake of emerging systemic and targeted therapies for hematologic malignancies
    • The implications of recent successes with maintenance therapy for standards of care in myeloma, FL, and other hematologic malignancies
  • Have increased confidence in their ability to:
    • Select optimal induction regimens for transplant-ineligible patients with multiple myeloma
    • Evaluate new frontline therapies such as R-bendamustine for CLL, FL, and other lymphoproliferative disorders
    • Recommend treatment strategies to minimize the risk of adverse effects for early or advanced HL
    • Compare second-generation TKIs to standard therapies for frontline and second-line treatment of CML
    • Use molecular biomarkers to guide treatment decisions and predict outcomes in AML and other hematologic malignancies
    • Use prognostic factors and risk models to guide treatment decisions for MPNs
    • Recommend optimal therapy for patients with MDS depending on age and risk group
  • Analyze emerging data on multiple hematologic malignancies and benign abnormalities toward improved patient outcomes
    • Molecular monitoring techniques for CML
    • Enrollment in clinical trials of novel agents for hematologic malignancies

Kenneth C. Anderson, MD 
Harvard University 
Dana-Farber Cancer Institute 
Boston, Massachusetts

Bruce D. Cheson, MD 
Georgetown University Hospital 
Washington, District of Columbia

Morton Coleman, MD
Center for Lymphoma and Myeloma 
Weill Cornell Medical College
New York-Presbyterian Hospital/
Weill Cornell Medical Center
New York, New York

Jorge E. Cortes, MD 
The University of Texas 
M. D. Anderson Cancer Center 
Houston, Texas

Michael W. N. Deininger, MD, PhD 
University of Utah 
Huntsman Cancer Institute 
Salt Lake City, Utah

John F. Dipersio, MD, PhD
Washington University
St. Louis, Missouri

Eric J. Feldman, MD 
Center for Lymphoma and Myeloma 
Weill Cornell Medical College
New York-Presbyterian Hospital/
Weill Cornell Medical Center
New York, New York

Alessandra Ferrajoli, MD 
The University of Texas 
M. D. Anderson Cancer Center 
Houston, Texas

Richard I. Fisher, MD 
University of Rochester 
Rochester, New York

Rafael Fonseca, MD 
Mayo Clinic 
Scottsdale, Arizona

Guillermo Garcia-Manero 
The University of Texas 
M. D. Anderson 
Houston, Texas

Morie A. Gertz, MD 
Mayo Clinic 
Rochester, Minnesota

Sergio A. Giralt, MD 
Memorial Sloan-Kettering Cancer Center 
New York, New York

Neil E. Kay, MD 
Mayo Clinic 
Rochester, Minnesota

John P. Leonard, MD 
Center for Lymphoma and Myeloma 
Weill Cornell Medical College
New York-Presbyterian Hospital/
Weill Cornell Medical Center
New York, New York

Brian K. Link 
University of Iowa 
Iowa City, Iowa

Sagar Lonial, MD 
Emory University 
Winship Cancer Center 
Atlanta, Georgia

Selina M. Lugar, MD
Abramson Cancer Center
University of Pennsylvania
Wynnewood, Pennsylvania

Robert Z. Orlowski, MD, PhD 
The University of Texas 
M. D. Anderson 
Houston, Texas

Animesh Pardanani, MBBS, PhD 
Mayo Clinic 
Rochester, Minnesota

Alfonso Quintas-Cardama, MD
The University of Texas
M. D. Anderson Cancer Center 
Houston, Texas

S. Vincent Rajkumar, MD 
Mayo Clinic 
Rochester, Minnesota

Charles A. Schiffer, MD 
Detroit Medical Center 
Karmanos Cancer Institute 
Detroit, Michigan

Thomas C. Shea, MD 
University of North Carolina 
Lineberger Comprehensive Cancer Center 
Chapel Hill, North Carolina

Richard T. Silver, MD, FACP
Center for Lymphoma and Myeloma 
Weill Cornell Medical College
New York-Presbyterian Hospital/
Weill Cornell Medical Center
New York, New York

David J. Straus, MD 
Memorial Sloan-Kettering Cancer Center 
New York, New York

Jeffrey A. Zonder, MD 
Wayne State University 
Karmanos Cancer Institute 
Detroit, Michigan

Thursday, April 28, 2011

12:00 pm
Registration

12:45 pm     
Introduction and ARS demographic/knowledge/confidence questions

Session I: Lymphoproliferative Disorders
Moderator – John P. Leonard, MD

1:00 pm
Debate: Is “Watch & Wait” still a reasonable strategy for low tumor burden, asymptomatic patients with advanced-stage FL?

Yes
Morton Coleman, MD

No
John P. Leonard, MD

1:30 pm
Debate: What is the optimal frontline therapy for a 63-year-old man with symptomatic advanced stage follicular lymphoma?

R-CHOP
Morton Coleman, MD

R-bendamustine
Bruce D. Cheson, MD

2:00 pm
Debate: What is the best management strategy for the younger, fit CLL patient who relapses within 2 years of completing frontline therapy?

Stem cell transplant
Thomas C. Shea, MD

Systemic therapy
Neil E. Kay, MD

2:30 pm
Coffee break

2:45 pm
Debate: What is the optimal management strategy for patients who respond to frontline therapy for advanced, symptomatic FL?

Consolidation therapy with radioimmunotherapy
Brian K. Link, MD

Maintenance therapy with rituximab
Morton Coleman, MD

3:15 pm
Debate: What is the optimal frontline therapy for symptomatic, previously untreated CLL?

FCR
Speaker invited

R-bendamustine
Bruce D. Cheson, MD

3:45 pm
Emerging novel therapies for CLL
Alessandra Ferrajoli, MD

How I Manage..

4:10 pm
17p and 11q deletions in CLL
Alessandra Ferrajoli, MD

4:20 pm
Early relapse after frontline FCR
Speaker invited

4:30 pm
CLL patients older than 70 years
Neil E. Kay, MD

4:40 pm
The decision to refer for allogeneic SCT
Bruce D. Cheson, MD

4:50 pm
Panel discussion

5:00 pm
Closing notes and end of day audience knowledge/competence questions via ARS

5:15 pm
Adjourn      

Friday, April 29, 2011

7:00 am
Continental Breakfast

8:00 am
Introduction and ARS demographic/knowledge/confidence questions

Session II: Multiple Myeloma
Moderator – Robert Z. Orlowski, MD, PhD

8:10 am
Debate: Is maintenance therapy a new standard of care for multiple myeloma patients responding to induction therapy and autologous SCT?

Yes, it improves PFS and TTP
Kenneth C. Anderson, MD

No, we need OS data and confirmatory studies
Sagar Lonial, MD

8:40 am
Debate: Are melphalan-prednisone–based regimens still the standard of care for frontline treatment of SCT-ineligible myeloma patients?

Yes
Robert Z. Orlowski, MD, PhD 

No
S. Vincent Rajkumar, MD

9:10 am
Debate: How important is complete remission in frontline therapy of myeloma?

Achieving CR is the holy grail of myeloma management
Kenneth C. Anderson, MD

CR is an illusion and does not equal cure
Rafael Fonseca, MD

9:30 am
The second wave of novel agents for multiple myeloma: Ripple or tsunami?
Kenneth C. Anderson, MD

10:00 am
Coffee break

Session III: Lymphomas
Moderator – John Leonard, MD

10:20 am
Debate: Is radiation therapy still necessary for early-stage classic Hodgkin's lymphoma?

Yes
Richard I. Fisher, MD

No
David J. Straus, MD

10:50 am
Debate: Should everyone with advanced-stage Hodgkin's lymphoma receive ABVD?

Yes
David J. Straus, MD

No, some patients require more aggressive systemic therapy
Richard I. Fisher, MD

How I Manage...

11:20 am
Radioimmunotherapy for B-cell lymphoma 
Brian K. Link, MD

11:30 am
Relapsed/refractory Hodgkin's lymphoma
David J. Straus, MD

11:40 am
Recurrent MCL in elderly patients
John P. Leonard, MD

11:50 am
CNS prophylaxis in DLBCL patients
Richard I. Fisher, MD

12:00 pm
Panel discussion

12:10 pm
Lunch with the professors

Session IV: Chronic Myelocytic Leukemia
Moderator – Jorge E. Cortes, MD

1:10 pm
What is the most appropriate frontline therapy for patients with newly diagnosed CML? Rationale of choosing imatinib or second generation TKIs
Jorge E. Cortes, MD

1:40 pm
Managing and monitoring your CML patients and their disease
Charles A. Schiffer, MD

2:05 pm
Debate: What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib?

Second-generation TKIs
Michael W. N. Deininger, MD, PhD

Allogeneic SCT
Sergio A. Giralt, MD

2:35 pm
Coffee break

2:50 pm
Debate: When phase II trials of a novel agent show dramatic improvements in clinical benefit compared to historical results for the previous standard of care, should randomized phase III trials still be required for approval?

Yes
S. Vincent Rajkumar, MD

No
Jorge E. Cortes, MD

3:20 pm
Emerging novel therapies for CML
Eric J. Feldman, MD

How I Manage…

3:45 pm
T315I mutations
Michael W. N. Deininger, MD, PhD

3:55 pm
Suboptimal response to frontline TKI therapy
Jorge E. Cortes, MD

4:05 pm
Toxicity of BCR-ABL TKIs
Charles A. Schiffer, MD

4:15 pm
Pregnancy in young CML patients
John F. DiPersio, MD, PhD

4:25 pm
Allogeneic SCT
Sergio A. Giralt, MD

4:35 pm
Panel discussion

4:45 pm
Closing notes and end of day audience knowledge/competence questions via ARS

5:00 pm
Adjourn


Saturday, April 30, 2011

7:00 am
Continental Breakfast

8:00 am
Welcome back and ARS demographic/knowledge/confidence questions

Session V: Multiple Myeloma
Moderator –Robert Z. Orlowski, MD, PhD

8:10 am
Debate: Is melphalan-dexamethasone still the standard of care for AL amyloidosis patients ineligible for transplant?

Yes
Morie A. Gertz, MD

No
S.Vincent Rajkumar, MD

8:40 am
Extramedullary myeloma: How common, how serious, how treatable?
Sagar Lonial, MD

How I Manage…

9:05 am
Renal Failure in Myeloma
Rafael Fonseca, MD

9:15 am
Myeloma patients > 80 years of age
Sagar Lonial, MD

9:25 am
Vertebral fractures in myeloma
Jeffrey A. Zonder, MD

9:35 am
Neuropathy in myeloma
Robert Z. Orlowski, MD, PhD

9:45 am
Panel discussion

10:00 am
Coffee break

Session VI: Myeloproliferative Neoplasms
Moderator –Richard T. Silver, MD, FACP

10:30 am
Prognostic factors and risk models in MPN
Alfonso Quintas-Cardama, MD

10:55 amDebate: Will JAK2 inhibitors prolong survival or simply improve symptoms and quality of life?

Prolong survival
Alfonso Quintas-Cardama, MD

Simply improve symptoms and quality of life
Animesh Pardanani, MBBS, PhD

11:25 am
Emerging biology and novel therapies beyond JAK2 inhibitors
Animesh Pardanani, MBBS, PhD

Session VII: Acute Leukemia and MDS
Moderator–Moderator invited

11:50 am What is the optimal induction therapy for young, low-intermediate risk AML patients?
Charles A. Schiffer, MD

12:20 pm
Lunch with the professors

1:20 pm
Debate: What is the current role of molecular biomarkers in AML?

Biomarkers can personalize therapy for AML
John F. DiPersio, MD, PhD

Biomarkers can determine prognosis, but cannot yet personalize therapy
Selina M. Luger, MD

1:50 pm
How I manage AML patients >75 years of age
Selina M. Luger, MD

2:05 pm
Coffee break

2:30 pm
Debate: What is the optimal therapy for younger, intermediate-2 and high-risk MDS patients?

More intermediate-2 and high-risk patients should be referred for allogeneic SCT
Eric J. Feldman, MD

Novel therapies offer greater hope than allogeneic SCT
Guillermo Garcia-Manero, MD

3:00 pm
Debate:What is the best management strategy for MDS patients responding to hypomethylating agent therapy?

Treat to best response and then observe
John F. DiPersio, MD, PhD

Treat to best response and then begin maintenance therapy
Eric J. Feldman, MD

3:30 pm
Emerging biology and novel therapeutic strategies for MDS
Guillermo Garcia-Manero, MD

3:50 pm
Closing notes and end of day audience knowledge/competence questions via ARS

4:05 pm
Adjourn

Information coming soon.

Discounted
If payment received by March 21, 2011

$199.00

Regular
If payment received by April 21, 2011

$249.00

Full/Onsite
If payment received after April 21, 2011

$299.00

Nurses/Residents/Students*
*proof of eligibility must accompany registration
*cannot be combined with any other discounts

$99.00

To Register: You may register online by April 21, 2011 at www.imedex.com, by calling Imedex at +1 (678) 242 0906, or by returning the registration form in this program by mail or fax +1 (678) 242-0920. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than April 21, 2011. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than April 21, 2011. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after April 21, 2011.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Conference Location and Registration
New York Marriott at the Brooklyn Bridge
333 Adams Street
Brooklyn, New York, 11201-3714
Tel.: +1 (718) 246-7000
Fax: +1 (718) 246-0563
www.marriott.com/brooklyn

The Registration and Information Desk will be staffed:

Thursday, April 28, 2011

12:00 PM – 5:15 PM

Friday, April 29, 2011

7:00 AM – 5:15 PM

Saturday, April 30, 2011

7:00 AM – 4:45 PM

New York Marriott at the Brooklyn Bridge
333 Adams Street
Brooklyn, New York, 11201-3714
Tel.: +1 (718) 246-7000
Fax: +1 (718) 246-0563
www.marriott.com/brooklyn

The New York Marriott at the Brooklyn Bridge is situated just across the river from Manhattan in New York City’s most celebrated neighborhood, Brooklyn Heights. These luxurious hotel rooms are an ideal choice among Brooklyn, New York hotels for both business and leisure travelers. Recently renovated, this hotel boasts a relaxed New York atmosphere with state-of-the-art hotel amenities and superior Marriott service. Cherished among hotels in Brooklyn, NY, the full-service Marriott Brooklyn hotel offers a unique blend of Brooklyn simplicity and New York City sophistication, just 1.5 miles from Manhattan.

For the convenience of attendees, a room block with a limited number of rooms has been reserved at the discounted group rate of $179.00 single/double occupancy, plus tax, currently 14.75%, and $3.50 occupancy tax per night. This limited number of discounted rooms will be available until April 6, 2011. This discounted rate is not guaranteed outside the conference dates. Reservations received after April 6, 2011 or after the room block has been filled (whichever comes first) are subject to availability and prevailing hotel rates.

To reserve your room please contact the New York Marriott at the Brooklyn Bridge reservations department at +1 (800) 266-9432 or visit the hotel’s website at https://resweb.passkey.com/go/updatesdebates. To receive the group rate, callers must identify themselves as being with the Great Debates and Updates in Hematologic Malignancies meeting. Reservation requests received after April 6, 2011 may not be guaranteed the group rate.

Conference Summary

Rather than focusing on one area within the field, this meeting will cover the broad continuum of hematologic malignancies, including lymphomas, leukemia’s and myeloma’s, in order to have the broadest appeal to attendees and provide the most substantial curriculum. This meeting will use a combination of didactic presentations of data in conjunction with a “debate” format in which recognized thought leaders will debate some of the most controversial topics in hematologic malignancies with a goal of providing the most thorough analysis of all currently available and emerging data.

Faculty and audience discussion will be fostered with a focus on how the new data fit into current community practice of hematologic Malignancies. This discussion will be aimed at facilitating rapid incorporation of important new advances in treatment into practice as well as assisting the participants, both from academic institutions and community-based settings, in identifying new areas of research covered in some of the above meetings that may not yet be ready to be used in community practice.

Who Should Attend

This educational program is specifically designed for academic and community hematologists, oncologists, oncology nurses and other healthcare professionals involved and/or interested in the treatment of patients with hematologic malignancies.

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Chairs:

John P. Leonard, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Robert Orlowski, MD, PhD
University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Last year’s conference featured debates on:

Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Lymphoma
Myeloma
Myeloproliferative Neoplasms
Myelodysplastic Syndromes

The following companies have provided an educational grant in support of this conference:

GOLD

Genentech/Biogen Idec

Millennium

SILVER

Cephalon

BRONZE

BMS

Celgene

Novartis Oncology

CORPORATE

Genzyme

Onyx

 

 

Several options are available to companies interested in supporting this conference.
For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.

Information coming soon.

The following companies are exhibitors at this conference:

Allos

BMS

Cancer Genetics

Celgene

Chephalon Oncology

Genentech

Millennium

Novartis

Onyx

Pfizer

Spectrum Pharmaceuticals

 

 

 

Opportunities are available to companies interested in exhibiting at this conference.
For more information, please contact Cori Gunter at +1 (678) 242 0712, or by email at c.gunter@imedex.com.